256 related articles for article (PubMed ID: 36271363)
1. Impact of hypoglycemia at the time of hospitalization for heart failure from emergency department on major adverse cardiovascular events in patients with and without type 2 diabetes.
Cha SA; Yun JS; Kim GH; Ahn YB
Cardiovasc Diabetol; 2022 Oct; 21(1):218. PubMed ID: 36271363
[TBL] [Abstract][Full Text] [Related]
2. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
Marx N; Kolkailah AA; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto RD; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK
JAMA Cardiol; 2024 Feb; 9(2):134-143. PubMed ID: 38170502
[TBL] [Abstract][Full Text] [Related]
3. Severe Hypoglycemia and Incident Heart Failure Among Adults With Type 2 Diabetes.
Echouffo-Tcheugui JB; Kaze AD; Fonarow GC; Dagogo-Jack S
J Clin Endocrinol Metab; 2022 Feb; 107(3):e955-e962. PubMed ID: 34741460
[TBL] [Abstract][Full Text] [Related]
4. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
[TBL] [Abstract][Full Text] [Related]
6. Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and Hypoglycemia.
Ebert T; Sattar N; Greig M; Lamina C; Froissart M; Eckardt KU; Floege J; Kronenberg F; Stenvinkel P; Wheeler DC; Fotheringham J
Am J Kidney Dis; 2024 Jan; 83(1):18-27. PubMed ID: 37657634
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
8. WBC count predicts heart failure in diabetes and coronary artery disease patients: a retrospective cohort study.
Kawabe A; Yasu T; Morimoto T; Tokushige A; Momomura SI; Sakakura K; Node K; Inoue T; Ueda S;
ESC Heart Fail; 2021 Oct; 8(5):3748-3759. PubMed ID: 34268904
[TBL] [Abstract][Full Text] [Related]
9. Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.
Guthrie R
Postgrad Med; 2020 May; 132(4):314-319. PubMed ID: 32164494
[TBL] [Abstract][Full Text] [Related]
10. Severe hypoglycemia and the risk of cardiovascular disease and mortality in type 2 diabetes: a nationwide population-based cohort study.
Yun JS; Park YM; Han K; Cha SA; Ahn YB; Ko SH
Cardiovasc Diabetol; 2019 Aug; 18(1):103. PubMed ID: 31412855
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular events and mortality among type 2 diabetes mellitus patients newly prescribed first-line blood glucose-lowering drugs monotherapies: A population-based cohort study in the Catalan electronic medical record database, SIDIAP, 2010-2015.
Herrera Comoglio R; Vidal Guitart X
Prim Care Diabetes; 2021 Apr; 15(2):323-331. PubMed ID: 33248925
[TBL] [Abstract][Full Text] [Related]
12. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
[TBL] [Abstract][Full Text] [Related]
13. Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care.
Morieri ML; Longato E; Di Camillo B; Sparacino G; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2022 Dec; 21(1):274. PubMed ID: 36494815
[TBL] [Abstract][Full Text] [Related]
14. Recurrent heart failure hospitalizations increase the risk of mortality in heart failure patients with atrial fibrillation and type 2 diabetes mellitus in the United Kingdom: a retrospective analysis of Clinical Practice Research Datalink database.
Lahoz R; Fagan A; McSharry M; Proudfoot C; Corda S; Studer R
BMC Cardiovasc Disord; 2022 May; 22(1):234. PubMed ID: 35597922
[TBL] [Abstract][Full Text] [Related]
15. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
Branch KRH; Dagenais GR; Avezum A; Basile J; Conget I; Cushman WC; Jansky P; Lakshmanan M; Lanas F; Leiter LA; Pais P; Pogosova N; Raubenheimer PJ; Ryden L; Shaw JE; Sheu WHH; Temelkova-Kurktschiev T; Bethel MA; Gerstein HC; Chinthanie R; Probstfield JL
Eur J Heart Fail; 2022 Oct; 24(10):1805-1812. PubMed ID: 36073143
[TBL] [Abstract][Full Text] [Related]
16. The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure.
Retwiński A; Kosmalski M; Crespo-Leiro M; Maggioni A; Opolski G; Ponikowski P; Poloński L; Jankowska E; Drzewoski J; Drożdż J
Kardiol Pol; 2018; 76(9):1336-1343. PubMed ID: 29862487
[TBL] [Abstract][Full Text] [Related]
17. Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome.
Rossello X; Ferreira JP; Caimari F; Lamiral Z; Sharma A; Mehta C; Bakris G; Cannon CP; White WB; Zannad F
Clin Res Cardiol; 2021 Oct; 110(10):1612-1624. PubMed ID: 33929598
[TBL] [Abstract][Full Text] [Related]
18. Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation.
Kwon CH; Kim YJ; Kim MJ; Cha MJ; Cho MS; Nam GB; Choi KJ; Kim J
Am J Cardiol; 2022 Sep; 178():35-42. PubMed ID: 35810007
[TBL] [Abstract][Full Text] [Related]
19. Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus.
Cherney DZI; Repetto E; Wheeler DC; Arnold SV; MacLachlan S; Hunt PR; Chen H; Vora J; Kosiborod M
Am J Nephrol; 2020; 51(1):74-82. PubMed ID: 31812955
[TBL] [Abstract][Full Text] [Related]
20. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
